Abstract 120P
Background
The prognostic importance of platelet-to-lymphocyte ratio(PLR)has been also investigated in some cancer types including colorectal cancer (CRC).Several studies have found that PLR is associated with poor prognosis in patients with CRC,but,the results are controversial.The aim of this study was to investigate the predictive and prognostic value of PLR,and the relationship between PLR and tumor localization.
Methods
A total of 201 patients with metastatic CRC and candidate to systemic treatments were retrospectively analyzed.Pretreatment complete blood cell count was evaluated to calculate PLR.The cutoff value for PLR was defined by the receiver operating characteristic(ROC)curve analysis and threshold value of 205.5 as best cut-off value was found.The prognostic and predictive significance of PLR was evaluated by univariate and logistic regression analysis.
Results
Significant relationship was detected between PLR and BRAF mutation,tumor localization.The higher rate of BRAF mutation was significantly detected for patients with PLRhigh(> 205.5)compared to those with PLRlow(<205.5)(p = 0.006).In addition,PLR was significantly higher in tumors located on the right colon than those with tumor on the left colon(p = 0.026).PLR, the presence of the primary tumor surgery, tumor localization, the presence of metastasectomy for progression-free survival(PFS)andPLR,age, BRAF mutation and the type of targeted therapy for overall survival(OS)were found to be prognostic factors by univariate analysis.Moreover,a logistic regression analysis indicated that PLR and the presence of metastasectomy were found to be an independent factors for predicting response to systemic treatment(p < 0.001,OR:0.30, 95%CI 0.16-0.34 and p = 0.020,OR: 0.40,95%CI 0.18-0.38,respectively).
Conclusions
Our results showed that pretreatment PLR was readily feasible and simple biomarker predicting response to treatment and survival,in addition it was significantly associated with tumor localization for patients with metastatic CRC.PLR may reflect immunogenic phenotype of patients with CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract